Review




Structured Review

Sebia Inc sebia flc elisa
Sebia Flc Elisa, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sebia+flc+elisa/assay+elisa+flc+sebia/pm42097195-109-1-1
Average 86 stars, based on 1 article reviews
sebia flc elisa - by Bioz Stars, 2026-09
86/100 stars

Images

Related Articles

Enzyme-linked Immunosorbent Assay:

Article Title: Discordant indirect immunofluorescence compared to multiplex bead immunoassay in ANCA associated vasculitides, a retrospective analysis
Article Snippet: .. Recently, other FLC assays have become available in the US, including the Sebia FLC ELISA, which employs rabbit polyclonal antibodies. .. The assays have similar reference intervals (RI), however differences in analytical performance between the FreeLite and Sebia were previously reported.

Article Title: Free light chain EQA: Analytical variability with clinical consequences - Data from 25 Italian EQA exercises (2021-2025).
Article Snippet: Serum free light chains (FLC) κ and λ, and the κ/λ ratio, are key biomarkers for the diagnosis, risk stratification and monitoring of monoclonal gammopathies.. However, substantial between-method variability still limits harmonised interpretation.. We analysed five years of external quality assessment (EQA) data from an Italian FLC scheme.

Article Title: Annual Meeting of the Royal Belgian Society of Laboratory Medicine: "Women's health: from puberty to menopause".
Article Snippet: .. For 2 patients, Diazyme FLC on Cobas c503 and Sebia FLC ELISA failed to detect a κ resp. λ sFLC antigen excess in the diagnostic sample. ..

Article Title: B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population
Article Snippet: citation ID: hvae106.698 B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population N. Krul, A. Olascoaga, E. Riva, G. Villanueva, L. Perez, A. Vallega, N. Correa, A. Trucido, J. Zipitria, A. Urbin, D. Garrido, F. Lemos, A. Acerbis, and R. Balleste Hospital de Clinicas, Montevideo, Uruguay Laboratory of Asistencial Médica, Maldonado, Uruguay Asociación Española, Montevideo, Uruguay BACKGROUND: Within the framework of a study to evaluate the Prevalence of Monoclonal Gammopathies in the Adult population of Uruguay through detection monoclonal bands by capillary electrophoresis and free light chains in serum, the aim is evaluating the comparison of quantification of FLC (Free Light Chains) in this group of patients with 2 assays: Freelite Biding Site® versus Sebia® FLC Elisa.. METHODS: Study period: September 2021 to November 2022.. Prospective, single-cohort, descriptive study.

Article Title: Comparative evaluation of free light chain assays in AL amyloidosis: Performance of Sebia versus Freelite and N-Latex
Article Snippet: .. This study evaluated the analytical performance and clinical utility of the Sebia FLC ELISA in newly diagnosed systemic AL amyloidosis, compared with Freelite and N-Latex. .. Our findings reveal substantial differences in quantitative FLC measurements with Sebia, particularly for λ involvement.

Article Title: Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis
Article Snippet: .. Sebia FLC ELISA can be used for the diagnosis of patients with AL amyloidosis, but its sensitivity should be improved, probably by redefining an appropriate reference range for the κ/λ ratio. ..

Article Title: Serum free light chain analysis: persisting limitations with new kids on the block.
Article Snippet: Objectives: Serum free light chain (sFLC) measurements have inherent analytical limitations impacting sFLC clinical interpretation.. We evaluated analytical and diagnostic performance of three polyclonal sFLC assays on four analytical platforms.. Methods: sFLC concentration was measured using Diazyme FLC assays (Diazyme) on cobas c501/c503 analyzer (Roche); Freelite assays (The Binding Site) on Optilite analyzer (The Binding Site) and cobas c501 analyzer and Sebia FLC ELISA assays (Sebia) on AP22 ELITE analyzer (DAS).

Produced:

Article Title: Free light chain EQA: Analytical variability with clinical consequences - Data from 25 Italian EQA exercises (2021-2025).
Article Snippet: Serum free light chains (FLC) κ and λ, and the κ/λ ratio, are key biomarkers for the diagnosis, risk stratification and monitoring of monoclonal gammopathies.. However, substantial between-method variability still limits harmonised interpretation.. We analysed five years of external quality assessment (EQA) data from an Italian FLC scheme.

Diagnostic Assay:

Article Title: Annual Meeting of the Royal Belgian Society of Laboratory Medicine: "Women's health: from puberty to menopause".
Article Snippet: .. For 2 patients, Diazyme FLC on Cobas c503 and Sebia FLC ELISA failed to detect a κ resp. λ sFLC antigen excess in the diagnostic sample. ..

Electrophoresis:

Article Title: B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population
Article Snippet: citation ID: hvae106.698 B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population N. Krul, A. Olascoaga, E. Riva, G. Villanueva, L. Perez, A. Vallega, N. Correa, A. Trucido, J. Zipitria, A. Urbin, D. Garrido, F. Lemos, A. Acerbis, and R. Balleste Hospital de Clinicas, Montevideo, Uruguay Laboratory of Asistencial Médica, Maldonado, Uruguay Asociación Española, Montevideo, Uruguay BACKGROUND: Within the framework of a study to evaluate the Prevalence of Monoclonal Gammopathies in the Adult population of Uruguay through detection monoclonal bands by capillary electrophoresis and free light chains in serum, the aim is evaluating the comparison of quantification of FLC (Free Light Chains) in this group of patients with 2 assays: Freelite Biding Site® versus Sebia® FLC Elisa.. METHODS: Study period: September 2021 to November 2022.. Prospective, single-cohort, descriptive study.

Comparison:

Article Title: B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population
Article Snippet: citation ID: hvae106.698 B-341 Comparative Study of Free Light Chains in the Framework of the Project Prevalence of Monoclonal Gammopathies in Adult Uruguayan Population N. Krul, A. Olascoaga, E. Riva, G. Villanueva, L. Perez, A. Vallega, N. Correa, A. Trucido, J. Zipitria, A. Urbin, D. Garrido, F. Lemos, A. Acerbis, and R. Balleste Hospital de Clinicas, Montevideo, Uruguay Laboratory of Asistencial Médica, Maldonado, Uruguay Asociación Española, Montevideo, Uruguay BACKGROUND: Within the framework of a study to evaluate the Prevalence of Monoclonal Gammopathies in the Adult population of Uruguay through detection monoclonal bands by capillary electrophoresis and free light chains in serum, the aim is evaluating the comparison of quantification of FLC (Free Light Chains) in this group of patients with 2 assays: Freelite Biding Site® versus Sebia® FLC Elisa.. METHODS: Study period: September 2021 to November 2022.. Prospective, single-cohort, descriptive study.

Biomarker Discovery:

Article Title: Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis
Article Snippet: .. Sebia FLC ELISA can be used for the diagnosis of patients with AL amyloidosis, but its sensitivity should be improved, probably by redefining an appropriate reference range for the κ/λ ratio. ..



Similar Products

86
Sebia Inc sebia flc elisa
Sebia Flc Elisa, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sebia+flc+elisa/assay+elisa+flc+sebia/pm42097195-109-1-1
Average 86 stars, based on 1 article reviews
sebia flc elisa - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Sebia Inc sebia flc elisa assay
Sebia Flc Elisa Assay, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sebia+flc+elisa/assay+elisa+flc+sebia/pmc12951226-57-1-1
Average 86 stars, based on 1 article reviews
sebia flc elisa assay - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Sebia Inc sebia flc elisa kappa lambda
Mechanisms of damage for free light chains. On the left, the direct cytotoxic effect of light chains on cells; on the right, the mass effect of amyloid deposition on tissue. In the myocardial cell on the left box, there is a brief representation of the molecular cascade of the direct damage .
Sebia Flc Elisa Kappa Lambda, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sebia+flc+elisa/assay+elisa+flc+sebia/pmc12524387-4-0-0
Average 86 stars, based on 1 article reviews
sebia flc elisa kappa lambda - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

86
Sebia Inc sandwich elisa based sebia flc assay
Morphology and Distribution of B Cell-derived and Non-B Cell-Derived Free Light Chains. This figure illustrates the typical morphological forms and tissue distributions of B cell-derived <t>free</t> <t>light</t> <t>chains</t> (B-FLCs) and non-B cell-derived free light chains (Non-B-FLCs). ( A ) B-FLCs predominantly deposit in the renal and cardiovascular systems, manifesting as crystalline inclusions in proximal tubule epithelial cells (light-chain proximal tubulopathy, LCPT), granular deposits in the glomerular basement membrane (light-chain deposition disease, LCDD), misfolded fibrils in the basement membrane, podocyte slit diaphragm, and cardiomyocyte extracellular matrix (AL amyloidosis), or uromodulin-bound casts in the distal tubule (light-chain cast nephropathy, LCCN). ( B ) Cancer-cell-derived or epithelial-cell-derived non-B-FLCs exist as extracellular amorphous monomers, dimers, polymers, and fibrils or are intracellularly located around the nucleus to display a filamentous network. Created in BioRender ( BioRender.com ). Li, L. (2025).
Sandwich Elisa Based Sebia Flc Assay, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sebia+flc+elisa/assay+elisa+flc+sebia/pmc12347604-220-35-37
Average 86 stars, based on 1 article reviews
sandwich elisa based sebia flc assay - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
Sebia Inc sebia® flc elisa
Morphology and Distribution of B Cell-derived and Non-B Cell-Derived Free Light Chains. This figure illustrates the typical morphological forms and tissue distributions of B cell-derived <t>free</t> <t>light</t> <t>chains</t> (B-FLCs) and non-B cell-derived free light chains (Non-B-FLCs). ( A ) B-FLCs predominantly deposit in the renal and cardiovascular systems, manifesting as crystalline inclusions in proximal tubule epithelial cells (light-chain proximal tubulopathy, LCPT), granular deposits in the glomerular basement membrane (light-chain deposition disease, LCDD), misfolded fibrils in the basement membrane, podocyte slit diaphragm, and cardiomyocyte extracellular matrix (AL amyloidosis), or uromodulin-bound casts in the distal tubule (light-chain cast nephropathy, LCCN). ( B ) Cancer-cell-derived or epithelial-cell-derived non-B-FLCs exist as extracellular amorphous monomers, dimers, polymers, and fibrils or are intracellularly located around the nucleus to display a filamentous network. Created in BioRender ( BioRender.com ). Li, L. (2025).
Sebia® Flc Elisa, supplied by Sebia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sebia+flc+elisa/sebia+flc+elisa/10__1093_slash_clinchem_slash_hvae106__698-0-126-126
Average 90 stars, based on 1 article reviews
sebia® flc elisa - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Mechanisms of damage for free light chains. On the left, the direct cytotoxic effect of light chains on cells; on the right, the mass effect of amyloid deposition on tissue. In the myocardial cell on the left box, there is a brief representation of the molecular cascade of the direct damage .

Journal: International Journal of Molecular Sciences

Article Title: Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis

doi: 10.3390/ijms26199511

Figure Lengend Snippet: Mechanisms of damage for free light chains. On the left, the direct cytotoxic effect of light chains on cells; on the right, the mass effect of amyloid deposition on tissue. In the myocardial cell on the left box, there is a brief representation of the molecular cascade of the direct damage .

Article Snippet: Sebia FLC ELISA kappa/lambda , Polyclonal , ELISA sandwich , AP22 Elite , - Larger measurement interval - Reduced repetitions needed for FLC quantification , - Proportional positive bias at high concentrations , - Quantitative with improved linearity across broad ranges.

Techniques:

Normal range of kappa/lambda FLC ratio Freelite ® assay. The serum quantification of free light chains (FLCs) and the kappa/lambda ratio vary according to renal function. ( a ) A normal kappa/lambda ratio in case of normal renal function (0.26–1.65) has a 100% negative predictive value for light-chain cardiac amyloidosis (AL-CA). If a kidney disease is present, the normal range is 0.37–3.10. ( b ) Comparison of two widely used serum free light chain (sFLC) assays. Freelite ® (The Binding Site, Birmingham, UK) uses polyclonal antibodies and is available on multiple clinical chemistry analyzers. N Latex FLC (Siemens Healthineers, Erlangen, Germany) employs a monoclonal antibody mixture and is available exclusively on Siemens nephelometric platforms.

Journal: International Journal of Molecular Sciences

Article Title: Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis

doi: 10.3390/ijms26199511

Figure Lengend Snippet: Normal range of kappa/lambda FLC ratio Freelite ® assay. The serum quantification of free light chains (FLCs) and the kappa/lambda ratio vary according to renal function. ( a ) A normal kappa/lambda ratio in case of normal renal function (0.26–1.65) has a 100% negative predictive value for light-chain cardiac amyloidosis (AL-CA). If a kidney disease is present, the normal range is 0.37–3.10. ( b ) Comparison of two widely used serum free light chain (sFLC) assays. Freelite ® (The Binding Site, Birmingham, UK) uses polyclonal antibodies and is available on multiple clinical chemistry analyzers. N Latex FLC (Siemens Healthineers, Erlangen, Germany) employs a monoclonal antibody mixture and is available exclusively on Siemens nephelometric platforms.

Article Snippet: Sebia FLC ELISA kappa/lambda , Polyclonal , ELISA sandwich , AP22 Elite , - Larger measurement interval - Reduced repetitions needed for FLC quantification , - Proportional positive bias at high concentrations , - Quantitative with improved linearity across broad ranges.

Techniques: Comparison, Binding Assay

Morphology and Distribution of B Cell-derived and Non-B Cell-Derived Free Light Chains. This figure illustrates the typical morphological forms and tissue distributions of B cell-derived free light chains (B-FLCs) and non-B cell-derived free light chains (Non-B-FLCs). ( A ) B-FLCs predominantly deposit in the renal and cardiovascular systems, manifesting as crystalline inclusions in proximal tubule epithelial cells (light-chain proximal tubulopathy, LCPT), granular deposits in the glomerular basement membrane (light-chain deposition disease, LCDD), misfolded fibrils in the basement membrane, podocyte slit diaphragm, and cardiomyocyte extracellular matrix (AL amyloidosis), or uromodulin-bound casts in the distal tubule (light-chain cast nephropathy, LCCN). ( B ) Cancer-cell-derived or epithelial-cell-derived non-B-FLCs exist as extracellular amorphous monomers, dimers, polymers, and fibrils or are intracellularly located around the nucleus to display a filamentous network. Created in BioRender ( BioRender.com ). Li, L. (2025).

Journal: International Journal of Molecular Sciences

Article Title: B Cell-Derived and Non-B Cell-Derived Free Light Chains: From Generation to Biological and Pathophysiological Roles

doi: 10.3390/ijms26157607

Figure Lengend Snippet: Morphology and Distribution of B Cell-derived and Non-B Cell-Derived Free Light Chains. This figure illustrates the typical morphological forms and tissue distributions of B cell-derived free light chains (B-FLCs) and non-B cell-derived free light chains (Non-B-FLCs). ( A ) B-FLCs predominantly deposit in the renal and cardiovascular systems, manifesting as crystalline inclusions in proximal tubule epithelial cells (light-chain proximal tubulopathy, LCPT), granular deposits in the glomerular basement membrane (light-chain deposition disease, LCDD), misfolded fibrils in the basement membrane, podocyte slit diaphragm, and cardiomyocyte extracellular matrix (AL amyloidosis), or uromodulin-bound casts in the distal tubule (light-chain cast nephropathy, LCCN). ( B ) Cancer-cell-derived or epithelial-cell-derived non-B-FLCs exist as extracellular amorphous monomers, dimers, polymers, and fibrils or are intracellularly located around the nucleus to display a filamentous network. Created in BioRender ( BioRender.com ). Li, L. (2025).

Article Snippet: Subsequent developments introduced alternative commercial serum FLC assays, including nephelometric methods like N-Latex FLC (Siemens; using monoclonal antibodies) and lateral flow methods like Seralite (Abingdon Health-Sebia; competitive inhibition lateral flow immunoassay), as well as the sandwich ELISA-based Sebia FLC assay (Sebia; using polyclonal antibody) [ , ].

Techniques: Derivative Assay, Membrane

Diverse Biological Functions of B Cell-Derived and Non-B Cell-Derived Free Light Chains. This figure illustrates B-FLCs/Non-B-FLCs’ diverse biological functions with currently elucidated molecular mechanisms, both physiologically and pathologically. ( A ) Classical B-FLCs participate in the formation of the antigen-binding region of intact immunoglobulins, interact with innate immune cells, e.g., mast cells and neutrophils in inflammation, perform enzymatic activity, e.g., anti-angiogenic, prothrombinase, and proteolytic activity, as well as function in damage to the cardiovascular system and renal system. ( B ) Non-B-FLCs exhibit distinct mechanistic roles: inflammasome activation in colitis, integrin-mediated FAK/SRC pathway activation in colon cancer progression, hepatoprotection via apoptosis inhibition during liver injury and promotion of hepatocellular carcinoma through ETFA binding and stabilization to enhance β-oxidation. Created in BioRender ( BioRender.com ). Li, L. (2025).

Journal: International Journal of Molecular Sciences

Article Title: B Cell-Derived and Non-B Cell-Derived Free Light Chains: From Generation to Biological and Pathophysiological Roles

doi: 10.3390/ijms26157607

Figure Lengend Snippet: Diverse Biological Functions of B Cell-Derived and Non-B Cell-Derived Free Light Chains. This figure illustrates B-FLCs/Non-B-FLCs’ diverse biological functions with currently elucidated molecular mechanisms, both physiologically and pathologically. ( A ) Classical B-FLCs participate in the formation of the antigen-binding region of intact immunoglobulins, interact with innate immune cells, e.g., mast cells and neutrophils in inflammation, perform enzymatic activity, e.g., anti-angiogenic, prothrombinase, and proteolytic activity, as well as function in damage to the cardiovascular system and renal system. ( B ) Non-B-FLCs exhibit distinct mechanistic roles: inflammasome activation in colitis, integrin-mediated FAK/SRC pathway activation in colon cancer progression, hepatoprotection via apoptosis inhibition during liver injury and promotion of hepatocellular carcinoma through ETFA binding and stabilization to enhance β-oxidation. Created in BioRender ( BioRender.com ). Li, L. (2025).

Article Snippet: Subsequent developments introduced alternative commercial serum FLC assays, including nephelometric methods like N-Latex FLC (Siemens; using monoclonal antibodies) and lateral flow methods like Seralite (Abingdon Health-Sebia; competitive inhibition lateral flow immunoassay), as well as the sandwich ELISA-based Sebia FLC assay (Sebia; using polyclonal antibody) [ , ].

Techniques: Derivative Assay, Binding Assay, Activity Assay, Activation Assay, Inhibition